Rubenstein David M.
Rubenstein David M., DIR, reported a transaction classified as grant at Moderna, Inc. involving 9681.000000 shares for an estimated $0.00. Reported holdings after the transaction were 9681.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- May 06, 2026
- Filing date
- May 08, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
MRNA price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- grant Code A
- Identifier
- 0001682852-26-000097 Stock Option (Right to Buy)
- Transaction date
- May 06, 2026 Filed May 08, 2026, 09:07 PM · 2d delay
- Shares
- 9,681 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 9,681 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-6 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
No officer title
- F1
This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
- F2
Restricted stock units convert into common stock on a one-for-one basis.
- F3
The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
0 other transactions
0 recent txs